Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease

It is a single-arm, single-center, open-label, single-dose study. A total of three subjects with severe sickle cell disease (SCD), aged 12-50 years (inclusive), are planned to receive cell infusion. After successful hematopoietic stem cell engraftment is achieved in the first subject, cell infusion will be initiated for subsequent subjects.

NCT Number	NCT07436767
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Sickle Cell Disease
Enrollment	3 participants
Start Date	2026-03-01
Primary Completion	2028-09-30 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-27